Abstract:Because the demand for rabies post exposure prophylaxis (PEP) treatment has increased exponentially in recent years, the limited supply of human and equine rabies immunoglobulin (HRIG and ERIG) has failed to provide an adequate amount of the required passive immune component in PEP in countries where canine rabies is endemic. The replacement of HRIG and ERIG with a potentially cheaper and efficacious alternative biological for the treatment of rabies in humans, therefore, remains a high priority. In this study, we set out to assess a human single-chain Fv antibody fragment fused with the Fc of an IgG1 targeting a rabies antigen to develop a product that can be used as a component of the PEP cocktail. We cloned the ScFv fragment from a human ScFv library that was established previously and inserted this fragment into the expression vector pPICZ alpha C/Fc. An active recombinant ScFv-Fc fusion protein was successfully expressed in Pichia pastoris. The production of ScFv-Fc was optimized and scaled up in an 80 L fermentor with yields exceeding 60 mg/L The ScFv-Fc protein was purified to more than 95% purity using a two-step scheme: ammonium sulfate fractionation and Protein A Sepharose CL-4B. The ScFv-Fc fusion protein neutralized rabies virus in a standard in vivo neutralization assay in which the virus was incubated with the ScFv-Fc molecules before intracranial inoculation in mice. Our results suggest that functional antibodies can be produced in P. pastoris and that ScFv-Fc fusion proteins have the potential to serve as therapeutic candidates. (C) 2012 Elsevier Inc. All rights reserved.

Generation and Characterization of the Human Neutralizing Antibody Fragment Fab091 Against Rabies Virus

Characterization Of A Human Antibody Fragment Fab And Its Calcium Phosphate Nanoparticles That Inhibit Rabies Virus Infection With Vaccine

Preparation and diagnostic use of a novel recombinant single-chain antibody against rabies virus glycoprotein

Expression, purification and characterization of a human single-chain Fv antibody fragment fused with the Fc of an IgG1 targeting a rabies antigen in Pichia pastoris.

A Novel Disulfide-Stabilized Single-Chain Variable Antibody Fragment Against Rabies Virus G Protein with Enhanced in Vivo Neutralizing Potency

A Novel Variable Antibody Fragment Dimerized by Leucine Zippers with Enhanced Neutralizing Potency Against Rabies Virus G Protein Compared to Its Corresponding Single-Chain Variable Antibody Fragment

Development of Human Monoclonal Antibodies With Broad Reactivity for Rabies Postexposure Prophylaxis

Characterization of a human–mouse chimeric monoclonal antibody targeting rabies virus glycoprotein

Development of a novel bispecific antibody GR1801 for rabies

A V-L-Linker-V-H Orientation Dependent Single Chain Variable Antibody Fragment Against Rabies Virus G Protein With Enhanced Neutralizing Potency In Vivo

Expression and Selection of Single-Chain Fv-Fc (scfv) Antibody Fragment Against Antigen of Rabies Virus in Pichia Pastoris

Immunogenicity and Antigenicity of the Ectodomain of Rabies Virus Glycoprotein Stably Expressed in HEK293T Cells

Construction and Screening of Human Immunized Phage-Display Antibody Libraries Against Rabies Virus

Preparation of Polyclonal Antibody Against Rabies Virus Glycoprotein Scfv Fragment Fv57

Purification and On-Column Refolding of a Single-Chain Antibody Fragment Against Rabies Virus Glycoprotein Expressed in Escherichia Coli.

Development of a novel method for detection of rabies virus neutralizing antibody

Engineering of a Novel Zipfv Using Leucine Zipper Motif Against Rabies Virus Glycoprotein G with Improved Protection Potency in Vivo.

Identification of binding epitope for anti-rabies virus glycoprotein single-chain Fv fragment FV57.

Preparation and Bioassay of Novel Human Anti-Gprv ScFv in E. Coli

Fusion Peptide Improves Stability and Bioactivity of Single Chain Antibody Against Rabies Virus

Efficient generation of monoclonal antibodies against major structural proteins of rabies virus with suckling mouse brain antigen.